TB-4 (Thymosin beta-4)
Formulation-specific trials · No established human subq dosing schedule
TB-4 is full-length thymosin beta-4. Human ocular, skin and IV studies do not establish a routine SubQ injury regimen. Formulation-specific trials · No established human subq dosing schedule.
Reviewed 2026-10-17. A source reference, not a personal treatment plan. Discuss treatment decisions with a qualified clinician.
Dose reference
| STUDY CONTEXT | Dose | Frequency | Context |
|---|---|---|---|
| Human SubQ dosing | Not established | No validated schedule | Human work with eye drops or IV preparations does not establish a weekly SubQ sports-injury cycle. A route-specific amount must stay with its exact formulation and trial. Source |
Human work with eye drops or IV preparations does not establish a weekly SubQ sports-injury cycle. A route-specific amount must stay with its exact formulation and trial.
Source context
ARISE-2 tested a defined ophthalmic thymosin beta-4 preparation for dry-eye outcomes. The full 43-residue peptide differs from both acetylated and unacetylated seven-residue fragments.
Reading the dose correctly
Human work with eye drops or IV preparations does not establish a weekly SubQ sports-injury cycle. A route-specific amount must stay with its exact formulation and trial.
Download the chart
Further reading
TB-4 (Thymosin beta-4) monograph on myPeptides
References
Why is there no numerical dose for TB-4 (Thymosin beta-4) on this card?
Human work with eye drops or IV preparations does not establish a weekly SubQ sports-injury cycle. A route-specific amount must stay with its exact formulation and trial.
Does a missing dose mean that no research exists?
This card describes formulation-specific trials. Evidence of a mechanism, a laboratory finding or an exposure does not by itself establish a useful and safe human treatment schedule. The monograph explains the distinction.